Navigation Links
New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer

Brian J. Druker and colleagues, investigators from the Howard Hughes Medical Institute, have developed a new technique that could help in identifying previously// unknown genetic mutations that can trigger cancerous growth. The researchers by using a new technique, where in they analyse the proteins instead of the genes, which are present inside acute myeloid leukemia (AML) cells, have significantly reduced the time it takes to target the molecular abnormalities that might be vulnerable to specific drug treatments.

"This approach gives us a way to figure out what's driving the growth of a cancer in an individual patient and ultimately match that patient with the right drug," said Druker, who is based at the Oregon Health & Science University in Portland. Druker's team collaborated on the research, which was published in the July 17, 2006, issue of the journal Cancer Cell, with scientists in the lab of D. Gary Gilliland, an HHMI investigator at Brigham and Women's Hospital, as well as researchers at the Portland VA Medical Center, Cell Signalling Technology, the University of Chicago, and Yale University.

Traditionally, cancer-gene hunters have scanned the genome looking for mutations that trigger out-of-control cell growth. Druker tried this approach, but found it wanting. "We were doing some high-throughput DNA sequencing, and we weren't really finding much," he said.

Instead, the team added tools from the burgeoning field of proteomics, the study of proteins. "We decided this more functional assay would get us to the disease-causing genes more rapidly," said Druker, who has been studying a group of cell-signalling proteins called tyrosine kinases for 20 years.

Tyrosine kinases play a key role in many cancers. In healthy cells, they help form a chain of signals that prompt normal cell growth and division. Sometimes, though, a tyrosine kinase gets stuck in an "on" position, driving out-of-control cell division and, ult imately, cancer. This potentially devastating kinase activation carries a calling card in the form of a molecule called a phosphate.

"The phosphates signal activated tyrosine kinases," said Druker. "So we decided to use the phosphates as markers."

To find these markers, the team took myeloid leukemia cells and chemically digested them into a mixture of protein snippets called peptides. Next, they extracted all of the peptides carrying extra phosphates and sent them through a mass spectrometer, which precisely measured the weight of each peptide. Sophisticated software then sifted through a massive protein database at the National Library of Medicine, identifying each of the team's peptides as a segment of a specific protein. The analysis showed that many of the peptides came from tyrosine kinases. Scanning this list, Druker picked out five as likely suspects.

Druker's team then introduced into their leukemia cells five segments of RNA that each shut down one of the candidate kinases. Silencing four of the kinases with RNA did nothing – the cells still grew out of control. But with the fifth, the cells no longer became cancerous.

"That left one gene to sequence. We found that the gene, called JAK3, had a mutation that drives the growth of leukemia cells in mice," said Druker. Analysis of additional patient samples later identified two more mutations in the JAK3 gene.

Thomas Mercher, a postdoctoral fellow in Gilliland's lab, then tested the mutation in a mouse model. "It was important to show that the JAK3 mutation, when introduced in mice, would lead to a leukemia-like illness. It did, confirming that the JAK3 mutations play a central role in leukemia," said Gilliland.

While Druker said that only a small proportion of AML patients likely carry JAK3 mutations, he says the technique will help find other cancer-causing mutations. The process is highly technical, but it cuts the time needed to find a faulty gene by months. "If you try to sift through DNA, it takes almost a year," said Druker. "This technique takes a couple of months and further automation would make it even quicker."

So quick, in fact, that Druker envisions the technique as a method to help choose which drug a patient's cancer will respond to – a critical step in achieving personalized medicine. Four cancer drugs that inhibit tyrosine kinases are already on the market, including Gleevec, which Druker pioneered for treatment of chronic myelogenous leukemia. Since its approval in 2001, Gleevec has made CML a much more manageable disease.

A new drug to inhibit JAK3 is already in development elsewhere, and, eventually; Druker sees a market filled with a dozen or more tyrosine kinase inhibitors. Matching the patient to the right drug will then simply be a matter of running their cancer cells through a future version of their new technique. Druker is already testing the idea. "Now we know to add JAK3 to the mutations we screen for in our leukemia patients and should look to see if JAK3 mutations are present in other cancers," he said.

Source: EurekAler.
'"/>




Related medicine news :

1. New Laser Techniques cure degeneration of the eye
2. New Technique to Study Infants Brain.
3. New Technique For Benign Breast Tumors
4. Preventing Strokes Using Less Invasive Techniques
5. New Technique To Detect Activity Of Drugs In The Body
6. New Technique To Test Stem Cells That Heal The Heart
7. A New Technique For Prediction Of Adult Height
8. Novel Technique For Targeting Small-Cell Lung Cancer
9. Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus
10. New Cardiac Angiography Technique For Improved Imaging Of Coronary Veins
11. New Technique Enables Better Nursing Of Robin Sequence Infants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... ... Controlling and maintaining the home’s water heater just got infinitely easier, more ... Controller , a first-of-its-kind system that enables remote and convenient control of a water ... for HVAC systems, Aquanta gives users a much more efficient, versatile way to use ...
(Date:5/24/2016)... Forest Lake, Minnesota (PRWEB) , ... May 24, ... ... his 13th mission trip to the Dominican Republic on September 21, 2016. Dr. ... Biology from Northwestern, serves with ChiroMission, a not-for-profit organization promoting health and wellness ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... , Out patient Services To Begin In June , Aloria Health, specializing in ... announce the opening of Aloria Milwaukee, its first treatment facility for outpatient, day ...
(Date:5/24/2016)... ... 2016 , ... "ProText Layouts Vol. 3 is a plugin that will keep ... Studios. , ProText Layouts Vol. 3 is a set of 30 self-animating kinetic text ... Layouts, video editors can create an lively typography video with incredible ease. Utilize intuitive ...
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a ... problem. A common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated ... orthopedic spine surgeon at Atlantic Spine Center . , So named because ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 ... for detection of multiple diseases; ,Technology to be presented ... Yissum Research Development Company of the Hebrew ... into a research agreement with Aurum Ventures MKI, the technology ... development of a new diagnostic approach for early detection ...
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
(Date:5/20/2016)... -- - Revenue Forecasts And R&D ... Recombinant Coagulation Factors and Regenerative Medicine ... Reveals Selling Opportunities and Revenue Prospects to Help ... the future of biologics, especially new drug classes? ... Staying ahead in data and knowledge, you benefit ...
Breaking Medicine Technology: